News - BioSpace
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.
BioSpace: Biotech, Pharmaceutical and Clinical Research News
Dec 11, 2010 · GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward accelerated approval in Huntington’s disease.
Stubborn Layoff Trend Continues Across Biopharma in 2024
6 days ago · 2023 was a tough year for the biopharma industry, with several companies downsizing and restructuring their workforces to stay afloat. And unfortunately, 2024 was more of the same, with some companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees.. BioSpace will continue to be your source of news on job cuts and restructuring ...
Join Our Team - BioSpace
BioSpace is the digital hub for life sciences news and jobs. Our mission is to provide essential insights, tools, and opportunities to connect the innovative organizations and talented professionals who advance health and quality of life across the globe.
About Us - BioSpace
BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
Wet Lab vs Dry Lab: Challenges, Benefits and Skills Required
Jan 25, 2023 · Wet Lab. Most web labs require at least a degree in chemistry or biology.However, there are some entry-level roles that require only a high school diploma. Soft skills, such as proper handling techniques, are vital in order to work in a wet lab.
ESSENCE Phase 3 trial results demonstrating statistically
The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed …
After Decades of Failure, First Disease-Modifying Huntington’s ...
Nov 11, 2024 · In September, Prilenia announced that the European Medicines Agency had accepted its marketing authorization application for pridopidine in Huntington’s disease. Prilenia’s submission is the first for an investigational drug with the potential to impact Huntington’s measures of clinical disease progression, according to the company’s press release.
Ei, A Pharmaceutical Solutionworks Joins NCRC To Bolster R&D
Jul 18, 2016 · KANNAPOLIS, N.C.--(BUSINESS WIRE)--Ei, A Pharmaceutical Solutionworks™ is moving a 24-person research and development team including three PhDs and nine Masters level scientists into a 10,000-square-foot laboratory with office space on the third floor of the David H. Murdock Core Laboratory Building on the NC Research Campus in Kannapolis, NC. ...
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets ...
Nov 14, 2024 · The FDA on Wednesday signed off on PTC Therapeutics’ gene therapy eladocagene exuparvovec-tneq for the treatment of aromatic L-amino acid decarboxylase deficiency. The treatment will be marketed under the brand name Kebilidi. With only around 350 cases reported in the literature, aromatic L-amino acid decarboxylase (AADC) deficiency is an ultrarare genetic disease characterized by severe ...